Skip to main content
ZNTL
NASDAQ Life Sciences

Matrix Capital Management Exits Zentalis Pharmaceuticals with $7.75M Share Sale

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.37
Mkt Cap
$98.984M
52W Low
$1.01
52W High
$3.33
52W Position info
36% above low
Off High info
59% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ZNTL sits 36% above its 52-week low of $1.01.

Summary

Matrix Capital Management, a former 10% owner, has fully exited its position in Zentalis Pharmaceuticals by selling 6.46 million shares for $7.75 million in a private transaction.


Key Events · Ownership and Investor Activity · ZNTL

  • Complete Institutional Exit

    Matrix Capital Management Company, LP, a former 10% owner, has filed an exit amendment to its Schedule 13D, indicating a full divestment of its holdings in Zentalis Pharmaceuticals, Inc.

  • Significant Share Sale

    The reporting persons sold 6,459,973 shares of common stock in a private transaction, representing a substantial portion of the company's outstanding shares.

  • Transaction Value

    The shares were sold at a price of $1.20 per share, totaling approximately $7.75 million.


Analysis · ZNTL · Life Sciences

Matrix Capital Management Company, LP, a significant institutional investor and former 10% owner, has fully divested its entire stake in Zentalis Pharmaceuticals. This complete exit, involving the sale of 6.46 million shares for approximately $7.75 million, represents a substantial portion of the company's market capitalization. The total liquidation of a major institutional position often signals a loss of conviction in the company's future prospects or a strategic reallocation of capital, which can be a strong negative indicator for other investors. The private sale occurred at $1.20 per share, below the current market price of $1.37.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZNTL was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $99M. The 52-week trading range was $1.01 to $3.33. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZNTL - Latest Insights

ZNTL
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.38 info
Change: -$0.360 (-21%) info
Market Cap: $133.642M info
ZNTL
Oct 23, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.38 info
Change: -$0.930 (-40%) info
Market Cap: $133.642M info
ZNTL
Oct 19, 2026, 2:31 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $1.38 info
Change: -$0.905 (-40%) info
Market Cap: $133.642M info
ZNTL
Oct 18, 2026, 6:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.38 info
Change: -$0.730 (-35%) info
Market Cap: $133.642M info
ZNTL
Aug 19, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.82
Real-time Price: $1.38 info
Change: -$2.44 (-64%) info
Market Cap: $133.642M info